Baudax Bio 관리
관리 기준 확인 2/4
We currently do not have sufficient information about the CEO.
주요 정보
Gerri Henwood
최고 경영자
n/a
총 보상
| CEO 급여 비율 | n/a |
| CEO 임기 | 5yrs |
| CEO 소유권 | 0.004% |
| 경영진 평균 재임 기간 | 1.1yrs |
| 이사회 평균 재임 기간 | 5yrs |
최근 관리 업데이트
Recent updates
Baudax Bio stock down after pricing $6.2M equity offering
Aug 30Baudax Bio to get US patent linked to pain drug Anjeso
Aug 22Baudax Bio GAAP EPS of -$1.05 beats by $0.22, revenue of $0.3M
Aug 11Cosette Pharmaceuticals appoints Rick Casten as CFO
Jul 06Baudax Bio: Looking For A Turnaround In Strong COVID-19 Headwinds
Sep 09A First Look At Baudax Bio
May 30Baudax Bio EPS misses by $0.08, misses on revenue
May 05Baudax Bio's Anjeso shows efficacy in pain management for total knee arthroplasty
Apr 26Have Insiders Been Buying Baudax Bio, Inc. (NASDAQ:BXRX) Shares?
Feb 17
Baudax Bio EPS of $0.62
Nov 09Baudax Bio: Why I'm Catching This Falling Knife
Nov 03CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Sep 30 2023 | n/a | n/a | -US$59m |
| Jun 30 2023 | n/a | n/a | -US$61m |
| Mar 31 2023 | n/a | n/a | -US$58m |
| Dec 31 2022 | US$663k | US$618k | -US$59m |
| Sep 30 2022 | n/a | n/a | US$13m |
| Jun 30 2022 | n/a | n/a | -US$67k |
| Mar 31 2022 | n/a | n/a | -US$11m |
| Dec 31 2021 | US$2m | US$618k | -US$20m |
| Sep 30 2021 | n/a | n/a | -US$66m |
| Jun 30 2021 | n/a | n/a | -US$38m |
| Mar 31 2021 | n/a | n/a | -US$53m |
| Dec 31 2020 | US$603k | US$309k | -US$76m |
| Sep 30 2020 | n/a | n/a | -US$66m |
| Jun 30 2020 | n/a | n/a | -US$88m |
| Mar 31 2020 | n/a | n/a | -US$69m |
| Dec 31 2019 | US$3m | US$46k | -US$33m |
| Sep 30 2019 | n/a | n/a | -US$42m |
| Jun 30 2019 | n/a | n/a | -US$51m |
| Mar 31 2019 | n/a | n/a | -US$61m |
| Dec 31 2018 | US$2m | US$599k | -US$74m |
보상 대 시장: Insufficient data to establish whether Gerri's total compensation is reasonable compared to companies of similar size in the US market.
보상과 수익: Gerri's compensation has been consistent with company performance over the past year.
CEO
Gerri Henwood (72 yo)
5yrs
테뉴어
US$663,224
보상
Dr. Geraldine A. Henwood, also known as Gerri, Ph D., has been the President, Chief Executive Officer and Director of Baudax Bio Inc. since 2019. She has been the Chief Development Officer of Iomab-B at Ac...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| President | 5yrs | US$663.22k | 0.0037% $ 0.2 | |
| Vice President of Financial Planning & Analysis | less than a year | 데이터 없음 | 데이터 없음 | |
| Consultant & Principle Accounting Officer | less than a year | 데이터 없음 | 데이터 없음 | |
| Chief Scientific Officer & Director | 1.3yrs | 데이터 없음 | 데이터 없음 |
1.1yrs
평균 재임 기간
53yo
평균 연령
경험이 풍부한 관리: BXRX.Q's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| President | 5yrs | US$663.22k | 0.0037% $ 0.2 | |
| Chief Scientific Officer & Director | 1.3yrs | 데이터 없음 | 데이터 없음 | |
| Independent Director | 5yrs | US$95.11k | 0.0022% $ 0.1 | |
| Independent Chairman | 5.8yrs | US$113.59k | 0.0020% $ 0.1 | |
| Independent Director | 4.3yrs | US$89.97k | 0.0020% $ 0.1 | |
| Independent Director | 5.8yrs | US$99.97k | 0.0020% $ 0.1 | |
| Independent Director | 4.3yrs | US$82.47k | 0.0020% $ 0.1 |
5.0yrs
평균 재임 기간
72yo
평균 연령
경험이 풍부한 이사회: BXRX.Q's board of directors are considered experienced (5 years average tenure).